转移性乳腺癌系统治疗中获得异常缓解患者的临床特征与长期结局
本回顾性单中心研究纳入2021至2023年58例转移性乳腺癌异常缓解患者,异常缓解定义为完全或部分缓解持续时间超过预期无进展生存期的两倍。5年无进展生存率为89.1%,5年总生存率为94.6%;完全缓解/无疾病证据状态与部分缓解相比5年总生存率显著更优(100% vs 83.0%,p=0.004)。11例患者在无疾病进展情况下停止治疗,其中仅1例部分缓解患者后续出现进展。
要点
- 58例异常缓解患者中,HER2阳性31例(53.5%)、HR阳性/HER2阴性16例(27.6%)、HR阴性/HER2阴性11例(19.0%)。
- 最佳影像学缓解为完全缓解/无疾病证据者占69.0%,部分缓解者占31.0%。
- 完全缓解/无疾病证据状态与部分缓解相比5年总生存率显著更优(100% vs 83.0%,p=0.004)。
核心结论
- 转移性乳腺癌中获得异常缓解的患者表现出良好的长期生存结局,尤其是达到完全缓解/无疾病证据者。
- 作者认为这些发现凸显了进一步研究以优化管理策略和探索系统治疗停药可能性的重要性。
研究设计与样本
- 回顾性单中心研究,纳入2021至2023年期间获得异常缓解的转移性乳腺癌患者。
- 异常缓解定义为完全缓解或部分缓解持续时间超过预期无进展生存期的两倍。
- 无疾病证据定义为整合局部区域治疗后达到影像学无疾病。
- 共识别58例异常缓解患者:HER2阳性31例(53.5%)、HR阳性/HER2阴性16例(27.6%)、HR阴性/HER2阴性11例(19.0%)。
主要发现
- 总体5年无进展生存率为89.1%,5年总生存率为94.6%。
- HR阴性/HER2阴性转移性乳腺癌5年无进展生存率/总生存率均为100%,数值上优于HER2阳性(90.2%/93.5%)和HR阳性/HER2阴性(80.8%/93.8%)。
- 最佳影像学缓解为完全缓解/无疾病证据者占69.0%,部分缓解者占31.0%。
- 完全缓解/无疾病证据状态与部分缓解相比5年总生存率显著更优(100% vs 83.0%,p=0.004)。
- 11例患者(9例完全缓解/无疾病证据,2例部分缓解)在无疾病进展情况下停止治疗;后续进展仅见于1例部分缓解患者。
关键数值与推荐
- 异常缓解定义为完全缓解或部分缓解持续时间超过预期无进展生存期的两倍。
- 无疾病证据定义为整合局部区域治疗后达到影像学无疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interest in metastatic solid tumors patients achieving exceptionally durable responses to systemic treatment is progressively increasing; however, available evidence still remains limited. This study characterizes patients with metastatic breast cancer (mBC) achieving an exceptional response, with a focus on patients discontinuing systemic treatment. METHODS: In this retrospective monocentric study, patients with mBC achieving exceptional responses (2021-2023) were identified; clinical features, hormone receptor (HR) and HER2 status, and radiological responses were collected. Exceptional response was defined as complete (CR) or partial response (PR) lasting for more than twice the expected progression-free survival (PFS). No evidence of disease (NED) was defined as radiological absence of disease achieved integrating locoregional treatments. RESULTS: We identified 58 exceptional responders: 31 HER2+ (53.5 %), 16 HR+ /HER2- (27.6 %), and 11 HR-/HER2- (19.0 %). 5-year PFS was 89.1 % and 5-year OS was 94.6 % overall, and numerically better in HR-/HER2- mBC (5-year PFS/OS: 100 %) compared to HER2+ (90.2 %/93.5 %) and HR+ /HER2- (80.8 %/93.8 %) mBC. Best radiological response was CR/NED in 69.0 % and PR in 31.0 % of patients. CR/NED status was significantly associated with better outcomes compared to PR (5-year OS: 100 % vs. 83.0 %, p = 0.004). Eleven patients (9 with CR/NED, 2 with PR) discontinued treatment in absence of disease progression; subsequent progression was observed only in one patient with PR. CONCLUSION: mBC patients achieving exceptional responses exhibit favorable long-term survival outcomes, particularly if achieving CR/NED. These findings highlight the importance of further research to refine management strategies and explore the potential for systemic treatment discontinuation in these patients.
引用
- Griguolo G, Bottosso M, Crema A, et al. Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes. Eur J Cancer. 2025. PMID: 39987798. doi:10.1016/j.ejca.2025.115321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。